BioAtla(BCAB) - 2023 Q4 - Annual Results

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 – CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 – CAB-AXL (BA3011) P ...